AME Signs Licensing Agreement With IDEXX For Diagnostic Development

Applied Molecular Evolution, Inc., has granted a non-exclusive sublicense to IDEXX Laboratories, Inc., for Applied Molecular Evolution’s (AME’s) Kauffman patents for directed evolution. IDEXX plans to use the Kauffman patents to develop diagnostic applications. “We believe that IDEXX’ decision to take this license reflects the value of our proprietary position in the field of directed Read more about AME Signs Licensing Agreement With IDEXX For Diagnostic Development[…]

Applied Molecular Evolution, Lilly Agree Second Collaboration

Applied Molecular Evolution Inc. (AME) has agreed to optimize an additional therapeutic antibody candidate for Eli Lilly and Co. In December 2001 AME announced its initial collaboration to optimize an antibody and a non-antibody protein therapeutic for Lilly. The goal of the current collaboration is to apply AME‘s proprietary AMEsystem directed molecular evolution technology to Read more about Applied Molecular Evolution, Lilly Agree Second Collaboration[…]